Palisade Bio (NASDAQ:PALI) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Palisade Bio (NASDAQ:PALI) from a hold rating to a sell rating in a research note published on Saturday.

PALI has been the topic of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research report on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $16.00.

Palisade Bio Trading Up 9.6%

Shares of PALI opened at $1.83 on Friday. The stock’s 50 day moving average is $1.90 and its two-hundred day moving average is $1.22. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.59. The firm has a market capitalization of $272.67 million, a PE ratio of -0.86 and a beta of 1.54.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.06). On average, sell-side analysts predict that Palisade Bio will post -12.43 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Palisade Bio stock. Armistice Capital LLC raised its holdings in Palisade Bio, Inc. (NASDAQ:PALI) by 37.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,764 shares of the company’s stock after buying an additional 39,397 shares during the quarter. Armistice Capital LLC owned approximately 3.29% of Palisade Bio worth $99,000 at the end of the most recent quarter. 11.79% of the stock is currently owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.